Analysts expect Tarsus Pharmaceuticals, Inc. to report revenue of 196.11 M for Q4 26, against a range of 189.89 M to 202.34 M. The most recent reported quarter, Q3 26, came in at 194.57 M, a 0.5% miss against the 195.48 M consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 66.41 M | 78.33 M | 102.66 M | 118.70 M | 151.67 M | 162.05 M | 173.91 M | 194.57 M | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | 58.96 M | 72.43 M | 92.29 M | 135.26 M | 144.81 M | 148.39 M | 186.21 M | 204.54 M | 202.34 M | 203.35 M | 236.71 M | 263.81 M | 337.92 M | 268.66 M | 271.61 M | 302.84 M | |||||||||
| Low Estimate | 51.62 M | 67.45 M | 85.88 M | 110.80 M | 126.78 M | 138.41 M | 166.91 M | 186.42 M | 189.89 M | 177.49 M | 194.60 M | 217.74 M | 279.58 M | 243.31 M | 244.11 M | 264.69 M | |||||||||
| Consensus Estimate | 55.29 M | 69.94 M | 89.08 M | 123.03 M | 135.80 M | 143.40 M | 176.56 M | 195.48 M | 196.11 M | 190.42 M | 215.66 M | 240.78 M | 308.75 M | 255.99 M | 257.86 M | 283.77 M |
Analysts expect Tarsus Pharmaceuticals, Inc. to report earnings per share of -0.06 for Q4 26, against a range of -0.06 to -0.06. The most recent reported quarter, Q3 26, came in at -14.40, a 914.1% miss against the -1.42 consensus.
| Metric | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.60 | -0.64 | -0.48 | -0.30 | -0.20 | -0.16 | -0.43 | -14.40 | - | - | - | - | - | - | - | - | |||||||||
| High Estimate | -0.69 | -0.68 | -0.34 | -0.34 | -0.08 | -0.38 | -0.19 | -1.35 | -0.06 | -0.28 | 0.04 | 0.14 | 3.65 | 0.81 | 0.25 | -1.78 | |||||||||
| Low Estimate | -0.75 | -0.74 | -0.38 | -0.40 | -0.08 | -0.44 | -0.21 | -1.49 | -0.06 | -0.34 | 0.04 | 0.12 | 3.03 | 0.67 | 0.21 | -1.90 | |||||||||
| Consensus Estimate | -0.72 | -0.71 | -0.36 | -0.37 | -0.08 | -0.41 | -0.20 | -1.42 | -0.06 | -0.31 | 0.04 | 0.13 | 3.34 | 0.74 | 0.23 | -1.84 |
Pull Wall Street consensus for Tarsus Pharmaceuticals, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=TARS&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "TARS", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=TARS&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();